In conclusion, considering all of the above-mentioned studies, as well as our study, it may be concluded that DNMT3A R882H mutations, which are usually observed in <20% of AML patients, may have a role in transforming blood cells to AML, but this event is a favorable prognostic factor. Here, DNMT3A is linked to acute myeloid leukemia.